Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2013

01-01-2013 | Letter to the Editor

Unincluded subjects need to be included for concerning the real association between TNFa−308 G/A polymorphism and cancer susceptibility

Authors: Guoqiang Zhang, Zengyan Liu, Xilong Wang, Zhongming Jia, Yong Han, Ye Bi, ShuJian Xu, Kai Cheng, Weiwei Zou, Zhenlin Yang

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Login to get access

Excerpt

To the Editor, …
Literature
1.
Shen C, Sun H, Sun D, Xu L, Zhang X, Liu A, Jia X, Bai J, Chen F, Yu Y, Jin Y, Yu J, Fu S (2011) Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis. Cancer Res Treat 126:763–770CrossRef
2.
Jaattela M (1991) Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest 64:724–742PubMed
3.
Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H (1999) Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 59:4516–4518PubMed
4.
Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M (1998) Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer Res 4:1743–1748PubMed
5.
Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE (1998) Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77:2246–2251PubMedCrossRef
6.
Hajeer AH, Hutchinson IV (2001) Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 62:1191–1199PubMedCrossRef
7.
Bouma G, Xia B, Crusius JB, Bioque G, Koutroubakis I, Von Blomberg BM, Meuwissen SG, Pena AS (1996) Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 103:391–396PubMedCrossRef
8.
Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R, Belaiche J (1998) Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113:401–406PubMedCrossRef
9.
Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW (1997) Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94:3195–3199PubMedCrossRef
10.
Mith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173CrossRef
11.
Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, Giacalone A, Di Noto L, Bongiovanni A, Raimondi C, Accardo A, Verna R, Candore G, Caruso C, Lio D, Palmeri S (2006) Cytokine Gene Polymorphisms and Breast Cancer Susceptibility. Ann N Y Acad Sci 1089:104–109PubMedCrossRef
12.
Gonullu G, Basturk B, Evrensel T et al (2007) Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J 28(11):1728–1733PubMed
Metadata
Title
Unincluded subjects need to be included for concerning the real association between TNFa−308 G/A polymorphism and cancer susceptibility
Authors
Guoqiang Zhang
Zengyan Liu
Xilong Wang
Zhongming Jia
Yong Han
Ye Bi
ShuJian Xu
Kai Cheng
Weiwei Zou
Zhenlin Yang
Publication date
01-01-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2347-3

Other articles of this Issue 2/2013

Breast Cancer Research and Treatment 2/2013 Go to the issue

Clinical trial

Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients

Epidemiology

Assessing interactions between the associations of fibroblast growth factor receptor 2 common genetic variants and hormone receptor status with breast cancer risk

Epidemiology

Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case–control study

Epidemiology

Impact of breast cancer on anti-mullerian hormone levels in young women

Epidemiology

Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry

Preclinical Study

Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits